One Integrated Solution For Meeting Your Preclinical To Clinical Drug Development Needs

As pharmaceutical and biotechnology companies become increasingly dependent on contract research organizations (CROs) to spearhead their preclinical and clinical research programs, and expedite the development pathway of their new therapies, choosing the right partner is more important than ever. We recently conducted a survey of over 143 biopharmaceutical executives to gain real-world perspective on the challenges they face, and shed some light on what motivates them to choose one CRO over another.1 The results provide insight into several areas:

• The significant challenges companies encounter when conducting preclinical and Phase I studies
• The unique difficulties of transitioning from preclinical to first-inhuman (FIH) studies
• The specific capabilities and expertise executives look for in their CRO partners

Steve Mason, Co-Chief Operating Officer at Altasciences, was also consulted for guidance on addressing these challenges and insight on the important characteristics that sponsor companies evaluate when choosing a CRO partner. We concluded that choosing a CRO capable of offering a fully integrated solution spanning all stages of preclinical and clinical development is a crucial element in overcoming many of the challenges identified.